Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective Effects of GSK1278863 on Exercise-Induced Muscle Damage
NCT02231190Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in muscle injury comparing GSK1278863 with Placebo (2 arms). Primary endpoint: Maximal voluntary contraction up to 72 hours. Started Jan 2015; status: completed.
02
Drugs
daprodustat
03
Conditions
muscle injury
Beyond the preview
Go deeper on NCT02231190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231190.